3628 results for «661»
3628 results
LDL-C management: should it begin in the cathlab?
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session examines the evolving role of LDL cholesterol management in patients undergoing percutaneous coronary intervention (PCI), with a focus on the potential benefits of initiating intensive lipid-lowering strategies early in the patient pathway.
The discussion reviews emerging evidence on PCSK9 inhibition in elective PCI...
Renal denervation 360°: are you ready for the future?
20 May 2026 – From EuroPCR 2026
Where does renal denervation (RDN) stand today, and where is it heading next?
This EuroPCR 2026 session provides a comprehensive update on RDN, covering its safe and effective use in line with the latest European recommendations. Faculty members share practical guidance on patient selection, programme implementation, and...
Active unloading with Impella heart pumps in elective and emergent patients
21 May 2026 – From EuroPCR 2026
This session presents the latest evidence on the use of microaxial Impella heart pumps in both elective high-risk and emergent cardiogenic shock patients. It highlights the importance of organised systems of care in improving survival outcomes and explores current data and expert consensus on mechanical circulatory...
Ascending into the future with drug-coated balloons
21 May 2026 – From EuroPCR 2026
Step into the future of interventional cardiology with comprehensive insights into drug‑coated balloons (DCB). This session covers the new DCB ARC guidelines, previews findings from the impactful BASKET BALL randomised trial, and examines real-world evidence from the SCORE registry. It also addresses the optimisation of acute...
Reshaping what's possible in complex PCI with advanced sirolimus technology
21 May 2026 – From EuroPCR 2026
Focused on advancing complex PCI, this session explores strategies to minimise metal use through advanced sirolimus technologies and drug-coated balloon (DCB) therapies. It highlights the biological and pharmacokinetic characteristics of DCBs, key device design considerations, and practical approaches to less-metal PCI. Clinical cases illustrate challenges such...
From 3D coronary imaging to calcium modification: the future of PCI starts now
21 May 2026 – From EuroPCR 2026
The integration of advanced imaging and calcium modification techniques is reshaping percutaneous coronary intervention (PCI), offering new ways to plan and optimise complex procedures.
This EuroPCR 2026 session explores how 3D coronary imaging extends beyond conventional angiography to improve procedural planning and decision-making. It highlights the role...
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Contemporary workflow for class IA PCI
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents a contemporary workflow for Class IA PCI, focusing on how coronary physiology can be used to better understand disease patterns and guide procedural strategy in complex interventions.
It explores the role of physiological assessment in refining decision-making, alongside new co- and tri-registration...
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
Beyond the horizon - A prelude into TAVI and complex PCI solutions
19 May 2026 – From EuroPCR 2026
This session provides a comprehensive preview of evolving technologies and strategies shaping interventional cardiology. Discover the Myval Octapro+ transcatheter heart valve (THV) and its innovative design and procedural benefits demonstrated through a recorded case. Stay updated on Landmark and Compare TAVI trial data, and discover the...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
TAVI and coronary artery disease: we need the COMPLETE answer!
19 May 2026 – From EuroPCR 2026
Addressing the intersection of transcatheter aortic valve implantation (TAVI) and coronary artery disease, this session reviews contemporary surgical and interventional literature to elucidate current practices. It underscores the need for a large international randomized controlled trial to provide definitive guidance for managing patients with concomitant aortic...
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
Large-bore venous access and vessel closure: all you need to know
19 May 2026 – From EuroPCR 2026
This session provides a comprehensive guide to large-bore venous access and vessel closure techniques, emphasizing best practices and the advantages of ultrasound-guided suture mediated vessel closure compared to traditional figure-of-eight suture methods. It also addresses strategies to avoid and manage potential complications encountered during these procedures.
Management of a patient with complex multivessel disease involving bifurcations
19 May 2026 – From EuroPCR 2026
Complex multivessel coronary disease involving bifurcations requires careful procedural planning, imaging guidance and tailored stent strategies.
This EuroPCR 2026 session combines live educational case with insights from the NAGOMI COMPLEX study to explore contemporary approaches to complex PCI. A key focus is placed on the role of...
Landmark interventional randomised controlled trial data and practice guidelines to transform pulmonary embolism care
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents landmark randomised controlled trial data shaping interventional treatment of pulmonary embolism, with a focus on translating evidence into clinical practice.
It reviews the HI-PEITHO trial and its implications in intermediate-risk acute PE, where ultrasound-assisted catheter-directed thrombolysis (USCDT) reduced the composite endpoint of...
Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach....
Align for the future with structural heart innovations - LIVE case and major trial updates
19 May 2026 – From EuroPCR 2026
Stay abreast of structural heart innovations with expert discussions on best-in-class transcatheter aortic valve implantation (TAVI) practices, including imaging, sizing, and procedural strategies. This session with LIVE case introduces the novel Myval Octapro+ transcatheter heart valve (THV), its design philosophy, and potential clinical benefits, along with...
